These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 37264449)

  • 1. Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.
    Murray JP; Pucci G; Weyer G; Ari M; Dickson S; Kerins A
    Addict Sci Clin Pract; 2023 Jun; 18(1):38. PubMed ID: 37264449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study.
    Bhatraju EP; Klein JW; Hall AN; Chen DR; Iles-Shih M; Tsui JI; Merrill JO
    J Addict Med; 2022 Jul-Aug 01; 16(4):461-465. PubMed ID: 34954743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
    Thakrar AP; Uritsky TJ; Christopher C; Winston A; Ronning K; Sigueza AL; Caputo A; McFadden R; Olenik JM; Perrone J; Delgado MK; Lowenstein M; Compton P
    Addict Sci Clin Pract; 2023 Feb; 18(1):13. PubMed ID: 36829242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study.
    Baumgartner K; Salmo E; Liss D; Devgun J; Mullins M; Galati B; Kelly J; Schwarz E
    Clin Toxicol (Phila); 2022 Jun; 60(6):688-693. PubMed ID: 35048759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of induction at standard doses of buprenorphine for inpatients with opioid use disorder.
    Schlechter C; Hossain R; Emerman CL
    J Addict Dis; 2022; 40(3):299-305. PubMed ID: 35133233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
    Azar P; Mathew N; Mahal D; Wong JSH; Westenberg JN; Schütz CG; Greenwald MK
    J Psychoactive Drugs; 2023; 55(1):94-101. PubMed ID: 35152847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.
    Nielsen S; Hillhouse M; Weiss RD; Mooney L; Sharpe Potter J; Lee J; Gourevitch MN; Ling W
    Am J Addict; 2014; 23(4):343-8. PubMed ID: 24112096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.
    Seval N; Nunez J; Roth P; Schade M; Strong M; Frank CA; Litwin AH; Levin FR; Brady KT; Nunes EV; Springer SA
    J Addict Med; 2023 Jul-Aug 01; 17(4):e232-e239. PubMed ID: 37579095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an intravenous low-dose buprenorphine initiation protocol.
    Jablonski LA; Bodnar AR; Stewart RW
    Drug Alcohol Depend; 2022 Aug; 237():109541. PubMed ID: 35753281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose Buprenorphine Initiation in Hospitalized Adults With Opioid Use Disorder: A Retrospective Cohort Analysis.
    Button D; Hartley J; Robbins J; Levander XA; Smith NJ; Englander H
    J Addict Med; 2022 Mar-Apr 01; 16(2):e105-e111. PubMed ID: 34001775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Low-dose Buprenorphine Initiation for Hospitalized Patients With Opioid Use Disorder.
    Sokolski E; Skogrand E; Goff A; Englander H
    J Addict Med; 2023 Jul-Aug 01; 17(4):e278-e280. PubMed ID: 37579112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
    Klaire S; Zivanovic R; Barbic SP; Sandhu R; Mathew N; Azar P
    Am J Addict; 2019 Jul; 28(4):262-265. PubMed ID: 30901127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose Initiation of Buprenorphine in Hospitalized Patients Using Buccal Buprenorphine: A Case Series.
    Adams KK; Cohen SM; Guerra ME; Weimer MB
    J Addict Med; 2023 Jul-Aug 01; 17(4):474-476. PubMed ID: 37579114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone micro-dosing - a case series.
    Brar R; Fairbairn N; Sutherland C; Nolan S
    Drug Alcohol Rev; 2020 Jul; 39(5):588-594. PubMed ID: 32657496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine Inductions via Transdermal Patches for Opioid Use Disorder in the Inpatient Setting.
    Porras H; Johnson E; Kotova M; Chenoweth J; Colby D
    J Pain Palliat Care Pharmacother; 2023 Sep; 37(3):251-256. PubMed ID: 37326470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.